Kornimate/medical-research-clean huggingface dataset:
evaluation of yoga for sleep disturbances in post traumatic stress disorder (ptsd)

Conditions: Post Traumatic Stress Disorder; Insomnia

Summary: the primary objective of this preliminary study is to estimate sleep outcome effect sizes and determine feasibility for a novel yoga treatment of insomnia in participants with post traumatic stress disorder (ptsd). additional objectives are to evaluate relationships of sleep outcomes with measures of other ptsd symptoms, psychosocial health and possible mechanisms of action.


Eligibility criteria:
inclusion criteria: * male and non-pregnant female adults at least 18 years of age. * a dsm-iv-tr diagnosis of post-traumatic stress disorder (ptsd). * naïve to yoga and other meditative practices, defined as less than one hour per week for the past 6 months. * potential subjects receiving ongoing medical or psychological treatment are eligible, as long as treatment remains stable over the course of the study and does not include more than one hour weekly of mind-body medicine (strategies directly related to meditation and yoga). * no more than 2 alcoholic or caffeinated drinks/day * no illicit drug use * potential subjects are eligible if they have been on stable dosage (not prn) of medication for ptsd symptoms including sleep disturbances and any medication that may influence sleep for at least 6 weeks prior to the study, and be willing to continue with same dosage for the duration of the study. * no current substance abuse, defined as diagnosis of substance abuse or dependence disorder within the past year, and/or in/outpatient treatment for substance abuse or dependence in the past 6 weeks. * no transcontinental travel over the course of the study. * no night-shift or rotating shift work over the course of the study. * insomnia based on the american academy of sleep medicine's research diagnostic criteria (rdc) for insomnia due to a mental health disorder * potential subjects are eligible to participate in this study if they have sufficient mental and physical ability to fully participate in the parameters of the study. subjects must be able to understand and comply with instructions in the group yoga sessions and home practice, complete questionnaires, participate in clinical interviews, and take part in all data collection activities. subjects with severe mental or physical concerns that may prevent them from understanding and/or complying with the treatment will be excluded. for example, potential subjects confined to wheelchairs will not be eligible, although subjects with artificial limbs who are able to reasonably participate in the intervention may be deemed eligible. these determinations will be made during discussions with potential subjects on a case by case basis during the screening process. exclusion criteria: - potential subjects are ineligible if pregnant.

Keywords: post traumatic stress disorder ptsd insomnia sleep yoga meditation mental health sleep quality actigraphy sleep diaries autonomic social health interoception attention regulation emotion regulation
effect of developmental care on very low birth weight infants

Conditions: Intervention

Summary: the goal of this clinical trial is to learn if developmental care works when implemented in very low birth weight infants. the main questions it aims to answer are: * does developmental care shorten the length of hospital stay in the very low birth weight infants? * does developmental care increase the opportunity of family centered care in the very low birth weight infants? the clinical trial will use a 36-month stepped-wedge cluster-randomised trial conducted across 40 neonatal intensive care units . a developmental care bundle will be tailored to meet the identified needs of participating nicus.

developmental care in the nicu focuses on creating a nurturing environment that supports the physical, emotional, and developmental needs of premature infants. this approach includes strategies like minimizing unnecessary noise and light, ensuring appropriate positioning and handling of infants, promoting skin-to-skin contact, and facilitating parental involvement in care. the clinical trial investigates the effectiveness of developmental care in very low birth weight (vlbw) infants. the primary objectives are to determine whether developmental care can (1) reduce the length of hospital stay and (2) enhance the opportunity for family-centered care in these infants. the study employs a 36-month stepped-wedge cluster-randomised trial design, involving 40 neonatal intensive care units (nicus). in this trial, all nicus will eventually receive the intervention, but the order in which they start implementing the developmental care bundle will be randomized. this approach allows each nicu to serve as its own control, comparing outcomes before and after the intervention. data collection will occur at multiple time points before and after the implementation of the developmental care bundle, enabling a comprehensive analysis of its impact. by tailoring interventions to each nicu's specific context and needs, the study aims to generate robust evidence on the benefits of developmental care for vlbw infants and their families.

Eligibility criteria:
inclusion criteria 1. birth weights less than 1500 g 2. admitted or transported to a level iii nicu within 24h of birth 3. oi\>30 exclusion criteria: 1. severe congenital malformations 2. various chromosomal disorders 3. genetic metabolic diseases, 4. severe neurological disorders

Keywords: developmental care
sous vide rewarming for frostbitten extremities

Conditions: Frostbite; Frostbite of Hand; Frostbite of Foot

Summary: the purpose of this study is to determine the efficacy of using sous vide devices for heating and maintaining the circulating warm water bath used in the rewarming of acute frostbite.


Eligibility criteria:
inclusion criteria: * age 18 or up * age \<17 with parent or guardian consent * ability to understand english * ability to provide consent to the study * acute frostbite of the hands or feet exclusion criteria: * children under age 18 without parent or guardian * frostbite that has already thawed * frostbite of tissue other than hands or feet * inability to understand english * inability to provide consent
diagnosis and treatment strategy optimization of severe pneumonia based on multi-omics data integration

Conditions: Severe Community-acquired Pneumonia

Summary: severe community-acquired pneumonia still has a high incidence and mortality, but the molecular mechanism and prognostic biomarkers of severe community-acquired pneumonia caused by different pathogens are still unclear, and the best treatment strategy has not been determined. based on this, this project intends to take patients with severe community-acquired pneumonia caused by different pathogens as the research object, explore the molecular mechanism of severe community-acquired pneumonia from multiple angles, integrate relevant research data to evaluate the rationality of initial empirical medication, and lay the foundation for precise treatment of severe pneumonia. the research results will help to develop a new rapid and accurate target for clinical diagnosis and efficacy evaluation of severe pneumonia, and build a precise treatment system for severe pneumonia.


Eligibility criteria:
inclusion criteria: age\> 18 years old clinical diagnosis of community-acquired pneumonia exclusion criteria: pregnancy, perinatal and lactating women combined immunosuppressive diseases: such as hiv, solid organ transplantation, solid organ/hematologic malignant tumor chemotherapy, rheumatic diseases or glomerular diseases need to take hormone/immunosuppressant therapy combined blood system diseases: such as leukemia reactions, aplastic anemia, neutropenia or deficiency of granulocytes, previous bone marrow/stem cell transplantation
evaluation of advanced imaging and visualization for clinical deep brain stimulation

Conditions: Deep Brain Stimulation

Summary: the objective of this project is to evaluate next generation visualization tools and surgical targeting models for clinical deep brain stimulation (dbs). this study will evaluate the performance of holodbs software in comparison to the current standard (soc) clinical planning tools to prepare for dbs surgery. the investigators hypothesize that holodbs will provide more detailed and anatomically useful information to the neurosurgeon and neurologist than the current clinical standard. the study team reviews electronic medical records (emr) from patients who are undergoing dbs surgery. there are no study visits involved in this study as only data from standard clinical care will be used. all study activities are executed by the study team and there are no interventions.


Eligibility criteria:
electronic medical records (emr) from all patients undergoing preoperative dbs evaluation will be reviewed and their data will be used for this study's purposes if they fit the inclusion and exclusion criteria. inclusion criteria: * age 18 years and over * meeting qualification for deep brain stimulation for parkinson's disease with one or more of medication refractory tremor, motor fluctuations despite medication optimization, or levodopa responsiveness but limited by medication induced adverse effects (nausea, dystonia, dyskinesia for example). exclusion criteria: * consideration of alternate diagnosis to parkinson disease * high risk medical comorbidities which would make the patient not a candidate for surgery.

Keywords: dbs parkinson's disease
retrospective chart review of subcutaneous igg use in infants

Conditions: Primary Immune Deficiency

Summary: this study is a retrospective chart review of the use of subcutaneous igg (scig) in infants less than two years old.


Eligibility criteria:
inclusion criteria: * infants who received more than one dose of igg by the subcutaneous route before the age of two years. * consent of parent/guardian if required by institution/irb. exclusion criteria: * infants with protein losing conditions such as lymphangiectasis, nephrosis, s/p cardio-thoracic surgery requiring drainage tubes for more than 48 hrs, protein losing enteropathy. * concomitant treatment with plasma, other blood products or igiv while on scig. * lack of consent by parent/guardian (if required by institution/irb). * any other condition or treatment which, in the opinion of the local investigator, would interfere with obtaining valid results for that subject.
relaxahead for headache patients (phase ii)

Conditions: Migraine; Headache; Multiple Sclerosis; Insomnia

Summary: the goal of this research is to assess the utility of smartphone-based progressive muscle relaxation (pmr) for the treatment of migraine and sleep. while there are many commercially available electronic diary and mind-body intervention apps for headache, there is little data showing their efficacy. relaxahead app incorporates the electronic pmr that was successfully used in an earlier epilepsy study and beta tested with headache specialist and migraine patient input. it also is an electric headache diary. the app has been studied and findings have been reported in multiple peer reviewed publications. also, the app has been updated based on prior feedback from the studies. now, this 2-arm randomized controlled study will evaluate the feasibility and acceptability of relaxahead for use with patients with migraine and comorbid insomnia. . one arm will be the relax group (the relaxahead app) and the other arm will be a monitored usual care (muc) group (this group receives standard of care and uses the electronic daily symptom reporting diary). the goals are to assess the feasibility and adherence of the relax intervention in persons with migraine and insomnia (aim 1) and to gather exploratory data on the effects of the relax intervention on headache and sleep related outcome measures (aim 2).


Eligibility criteria:
inclusion criteria: * age 18-80 years (age 18-65 in urgent care); * meets migraine criteria based on the international classification of headache disorders (ichd) criteria; * migraine disability assessment (midas) score \>5. 4+ headache days a month or; meets chronic post- traumatic headache (pth) criteria based on international classification of headache disorders (ichd) criteria, is 3-12 months post-injury, and there are 4+ headache days a month. * scoring \> or = 15 on the isi. exclusion criteria: * patients who have had cognitive behavioral therapy, biofeedback, or other relaxation therapy in the past year; * cognitive deficit or other physical problem with the potential to interfere with behavioral therapy; * alcohol or other substance abuse as determined by self-report or prior documentation in the medical record; * opioid or barbiturate use 10+ days a month; * unable or unwilling to follow a treatment program that relies on written and audio file materials; * not having a smartphone.

Keywords: progressive muscle relaxation therapy migraine insomnia
structural conditions and health after release from prison

Conditions: Cardiovascular Diseases; Health Care Utilization

Summary: people released from prison experience two times higher cardiovascular (cv) mortality than the general population, have a high prevalence of poor cv health and increased risk of cv events within 2 years of release. access to high quality healthcare following release from prison is key to preventing poor health and cv outcomes. our study team will investigate facilitators and barriers to health care access experienced by people released from prison.

upon release from prison, people face numerous challenges including unstable housing, limited employment, stigma, and poor health. structural conditions in healthcare systems, including policies, practices and attitudes around healthcare access, transition programs, culture, support of social determinants of health, and specialized services for people released from prison, may influence access and health outcomes for people released from prison. we will enroll people released from prison into a prospective cohort study to examine the association between exposure to structural conditions and 12-month primary outcomes of healthcare utilization (clinic visits, emergency visits, hospitalization) and secondary outcomes of cv hospitalization and all-cause mortality. moderation by participant characteristics such as self-reported race, ethnicity, gender, age and baseline cv health will be tested.

Eligibility criteria:
inclusion criteria: * recenlty released from state prison into the denver/aurora colorado metro area * age 18 and older * ability to understand study procedures in english or spanish * no plans to leave the area for six months exclusion criteria: * on "current inmate" status or still under correctional observation (i.e., under locked confinement part of the day or night) * plans to leave area within six months * unable to consent
improving bowel preparation for colonoscopy with a simple educational card

Conditions: Colonic Polyps; Colonic Neoplasms

Summary: the purpose of this study is to determine whether adding a simple educational card to standard pre-procedure instructions improves the quality of bowel preparation for colonoscopy.

despite written instructions, many patients do not understand the importance of bowel preparation as they prepare for colonoscopy. this often leads to poor compliance with preparation protocol and therefore inadequate bowel preparation. our goal is to include a simple educational card which will hopefully improve the quality of bowel preparation by providing a visual component with the preparation instructions. this card will stress the importance of drinking the entire bowel preparation and provide representative images of a dirty and clean colon. we will specifically target patients directly booked for screening colonoscopy (those without a pre-procedure office visit). in a randomized fashion, patients in the control group will receive the standard bowel preparation instructions and patients in the intervention group will receive the educational card along with the standard bowel preparation instructions. the primary outcome will be the endoscopist's assessment of the quality of preparation using a standardized bowel preparation scale. secondary outcomes will include the number and types of polyps found, colonoscope insertion and withdrawal time, and patient satisfaction with the procedure.

Eligibility criteria:
inclusion criteria: * outpatients * 18 years old or older * referred and scheduled for an elective screening colonoscopy exclusion criteria: * inpatients * prisoners * cognitively impaired patients * legally blind patients * patients allergic to polyethylene glycol electrolyte lavage solution

Keywords: colonoscopy bowel preparation patient education polyp detection
lonquek for autologous stem cell mobilization

Conditions: Lymphoma; Multiple Myeloma

Summary: the aim of this study is to evaluate the efficacy and tolerability of lonquek which is a pegylated (long-acting) version of filgrastim recombinant human g-csf (g-csf) in mobilizing sufficient number of stem cells for autologous stem cell transplantation in patients with lymphoma and multiple myeloma.


Eligibility criteria:
inclusion criteria: * patients with confirmed multiple myeloma or hodgkins or non hodgkin lymphoma at need of autologous stem cell transplantation. * disease must be chemosensitive or stable status to prior therapy before transplant. * age between 18 and 65 years inclusive. * ecog performance status 0, 1 or 2. * written informed consent. * adequate birth control in fertile patients. exclusion criteria: * lymphoma patients that did not fulfill the inclusion criteria. * patients with factors predicting poor mobilization including \>3 lines of previous chemotherapy, extensive irradiation, patients that received stem cell toxicity drugs like melphalan, fludarabine, \>2 courses of revlimid, age \>65 years, platelets counts \ 35x109/l. * previous autologous stem cell transplantation. * inability to tolerate peripheral blood stem cell harvest. * peripheral venous access not possible.

Keywords: lymphoma multiple myeloma stem cell mobilization autologous stem cell transplantation
a study evaluating the efficacy and safety of sildenafil in men with traumatic spinal cord injury and erectile dysfunction

Conditions: Spinal Cord Injury; Erectile Dysfunction; Spinal Cord Trauma; Injuries, Spinal Cord; Impotence

Summary: to demonstrate the efficacy, safety and tolerability of sildenafil administered orally, as required, approximately 1 hour prior to sexual activity to men with erectile dysfunction (ed) associated with spinal cord injury (sci), as well as its effects on the quality of life (qol) of these patients.


Eligibility criteria:
inclusion criteria: -patients were men with spinal cord injury and erectile dysfunction exclusion criteria: -n/a
study of cep-701 (lestaurtinib) in patients with acute myeloid leukemia (aml)

Conditions: Acute Myeloid Leukemia

Summary: the purpose of the study is to determine whether cep-701 given in sequence with induction chemotherapy increases the proportion of patients with relapsed acute myeloid leukemia (aml) who achieve a second complete remission (cr).

patients randomly assigned to chemotherapy alone received the second course of induction chemotherapy as soon as clinically indicated; patients randomly assigned to receive chemotherapy plus sequential lestaurtinib had lestaurtinib withheld for 3 days (72 hours) before the start of the second 5-day course of chemotherapy and resumed lestaurtinib treatment 2 days (48 hours) after the final administration of the second course of chemotherapy.

Eligibility criteria:
inclusion criteria: * cytological confirmation of aml; * relapsed disease following first cr of 1 month(30days)to 24 months(730days). the time from first relapse to study entry (start of first course of induction chemotherapy) must be no longer than 30days; * confirmation of flt-3 activating mutation positive status after point of initial relapse; * aged 18 years or older; * written informed consent; * ability to understand and comply with study restrictions; * no comorbid conditions that would limit life expectancy to less than 3 months; * ecog performance score of 0, 1,or 2; * women must be neither pregnant nor lactating, and either of non-childbearing potential or using adequate contraception with a negative pregnancy test at study entry exclusion criteria: * bilirubin \> 2x uln; * alt/ast \> 3x uln; * serum creatinine \> 1.5 mg/dl; * resting ejection fraction of left ventricle l \< 45%(applies only to patients scheduled to receive mitoxantrone, etoposide, and cytarabine \[mec\]; * untreated or progressive infection; * any physical or psychiatric cdtn that may compromise participation in the study; * known cns involvement with aml; * any previous treatment with a flt-3 inhibitor; * requires current treatment for hiv with protease inhibitors; * active gi ulceration or bleeding; * use of an investigational drug that is not expected to be cleared by the start of cep-701 treatment

Keywords: aml
a comparison of sertraline versus venlafaxine xr in the treatment of major depression

Conditions: Depressive Disorder, Major

Summary: to assess the comparative efficacy of sertraline versus venlafaxine xr on measures of quality of life.


Eligibility criteria:
inclusion criteria: * primary diagnosis of dsm-iv major depressive disorder, single episode or recurrent, without psychotic features. additional dsm-iv axis i diagnoses will be permitted only if they are identified as secondary diagnoses. * hamilton-depression rating scale (ham-d; 17 item) total score ≥18 and hamd item 1 (depressed mood) score ≥2. exclusion criteria: * use of an antidepressant within 2 weeks of baseline (4 weeks for fluoxetine) * current or past diagnosis of bipolar disorder or any psychotic disorder.
holmium radioembolization as adjuvant treatment to rfa for early stage hcc: dose finding study

Conditions: HCC; Early Stage HCC

Summary: in this multi-center, dose-finding study, patients with early stage hepatocellular carcinoma according to the barcelona clinic liver cancer (bclc) staging system will be included to receive percutaneous radiofrequency ablation in combination with rfa with adjuvant segmental radioembolization.

rfa + adjuvant radioembolsation with quirem spheres

Eligibility criteria:
inclusion criteria: * informed consent * age \> 18 years * single hcc lesion with diameter of ≥ 2-5cm or up to three lesions with each lesion measuring no more than 3cm (confined to one lobe) * hcc diagnosis is based on histology or non-invasive imaging criteria according to eortc-easl guidelines * child pugh a or b ≤7 * ecog performance status ≤ 2 * bilirubin \< 2mg/dl * asat \< 5x upper limit of normal * alat \< 5x upper limit of normal * thrombocytes ≥ 50 x 10\^9/l exclusion criteria: * recurrent hcc * tumor location precluding percutaneous rfa * bilobar tumor involvement * vascular tumor invasion or extrahepatic metastasis * hemihepatectomy * severe comorbidity (e.g. cardiovascular disease, diabetes with nephropathy, active infections) * uncorrectable coagulopathy * large arterio-portovenous shunt * previous radiotherapy to the liver * surgical hepatico-enterostomy * hepatic resection with placement of surgical clips that may cause artefacts on mri * incompetent/ mentally disabled * pregnancy, inadequate anticonception * calculated lung dose \>30gy * creatinine clearance \< 50 ml/min

Keywords: hepatocellular carcinoma radiofrequency ablation (rfa) radioembolization quirem spheres selective internal radiation therapy